Microbiome Sex-Related Diversity in Non-Muscle-Invasive Urothelial Bladder Cancer
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Bacterial DNA Isolation
2.3. 16S rRNA Gene Analysis
2.4. Statistical and Bioinformatic Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Saginala, K.; Barsouk, A.; Aluru, J.S.; Rawla, P.; Padala, S.A.; Barsouk, A. Epidemiology of Bladder Cancer. Med. Sci. 2020, 8, 15. [Google Scholar] [CrossRef] [PubMed]
- Mancini, M.; Righetto, M.; Baggio, G. Spotlight on gender-specific disparities in bladder cancer. Urologia 2020, 87, 103–114. [Google Scholar] [CrossRef] [PubMed]
- Dobruch, J.; Daneshmand, S.; Fisch, M.; Lotan, Y.; Noon, A.P.; Resnick, M.J.; Shariat, S.F.; Zlotta, A.R.; Boorjian, S.A. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur. Urol. 2016, 69, 300–310. [Google Scholar] [CrossRef] [PubMed]
- Mun, D.-H.; Kimura, S.; Shariat, S.F.; Abufaraj, M. The impact of gender on oncologic outcomes of bladder cancer. Curr. Opin. Urol. 2019, 29, 279–285. [Google Scholar] [CrossRef] [PubMed]
- Jobczyk, M.; Pikala, M.; Różański, W.; Maniecka-Bryła, I. Years of life lost due to bladder cancer among the inhabitants of Poland in the years 2000 to 2014. Cent. Eur. J. Urol. 2017, 70, 338–343. [Google Scholar] [CrossRef]
- Goessl, C.; Knispel, H.H.; Miller, K.; Klän, R. Is routine excretory urography necessary at first diagnosis of bladder cancer? J. Urol. 1997, 157, 480–481. [Google Scholar] [CrossRef] [PubMed]
- Palou, J.; Rodríguez-Rubio, F.; Huguet, J.; Segarra, J.; Ribal, M.J.; Alcaraz, A.; Villavicencio, H. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J. Urol. 2005, 174, 859–861; discussion 861. [Google Scholar] [CrossRef] [PubMed]
- Garg, T.; Pinheiro, L.C.; Atoria, C.L.; Donat, S.M.; Weissman, J.S.; Herr, H.W.; Elkin, E.B. Gender disparities in hematuria evaluation and bladder cancer diagnosis: A population based analysis. J. Urol. 2014, 192, 1072–1077. [Google Scholar] [CrossRef] [PubMed]
- Burger, M.; Catto, J.W.F.; Dalbagni, G.; Grossman, H.B.; Herr, H.; Karakiewicz, P.; Kassouf, W.; Kiemeney, L.A.; La Vecchia, C.; Shariat, S.; et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 2013, 63, 234–241. [Google Scholar] [CrossRef]
- Sylvester, R.J.; Rodríguez, O.; Hernández, V.; Turturica, D.; Bauerová, L.; Bruins, H.M.; Bründl, J.; van der Kwast, T.H.; Brisuda, A.; Rubio-Briones, J.; et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur. Urol. 2021, 79, 480–488. [Google Scholar] [CrossRef]
- Apollo, A.; Ortenzi, V.; Scatena, C.; Zavaglia, K.; Aretini, P.; Lessi, F.; Franceschi, S.; Tomei, S.; Sepich, C.A.; Viacava, P.; et al. Molecular characterization of low grade and high grade bladder cancer. PLoS ONE 2019, 14, e0210635. [Google Scholar] [CrossRef]
- Herr, H.W. Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J. Urol. 2000, 163, 60–61; discussion 61–62. [Google Scholar] [CrossRef]
- Bree, K.K.; Hensley, P.J.; Lobo, N.; Brooks, N.A.; Nogueras-Gonzalez, G.M.; Guo, C.C.; Navai, N.; Grossman, H.B.; Dinney, C.P.; Kamat, A.M. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors. J. Urol. 2022, 208, 284–291. [Google Scholar] [CrossRef] [PubMed]
- Cheng, L.; Montironi, R.; Davidson, D.D.; Lopez-Beltran, A. Staging and reporting of urothelial carcinoma of the urinary bladder. Mod. Pathol. 2009, 22 (Suppl. S2), S70–S95. [Google Scholar] [CrossRef]
- Choi, W.; Ochoa, A.; McConkey, D.J.; Aine, M.; Höglund, M.; Kim, W.Y.; Real, F.X.; Kiltie, A.E.; Milsom, I.; Dyrskjøt, L.; et al. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset. Eur. Urol. 2017, 72, 354–365. [Google Scholar] [CrossRef] [PubMed]
- Siracusano, S.; Rizzetto, R.; Porcaro, A.B. Bladder cancer genomics. Urologia 2020, 87, 49–56. [Google Scholar] [CrossRef]
- Salagierski, M. The genetic patterns of bladder cancer. Where do we stand now? Cent. Eur. J. Urol. 2014, 66, 411–412. [Google Scholar] [CrossRef] [PubMed]
- Hussain, S.A.; Palmer, D.H.; Syn, W.-K.; Sacco, J.J.; Greensmith, R.M.D.; Elmetwali, T.; Aachi, V.; Lloyd, B.H.; Jithesh, P.V.; Arrand, J.; et al. Gene expression profiling in bladder cancer identifies potential therapeutic targets. Int. J. Oncol. 2017, 50, 1147–1159. [Google Scholar] [CrossRef]
- Knowles, M.A.; Hurst, C.D. Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 2015, 15, 25–41. [Google Scholar] [CrossRef]
- Yoshino, H.; Seki, N.; Itesako, T.; Chiyomaru, T.; Nakagawa, M.; Enokida, H. Aberrant expression of microRNAs in bladder cancer. Nat. Rev. Urol. 2013, 10, 396–404. [Google Scholar] [CrossRef]
- Kiselyov, A.; Bunimovich-Mendrazitsky, S.; Startsev, V. Key signaling pathways in the muscle-invasive bladder carcinoma: Clinical markers for disease modeling and optimized treatment. Int. J. Cancer 2016, 138, 2562–2569. [Google Scholar] [CrossRef] [PubMed]
- Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014, 507, 315–322. [CrossRef] [PubMed]
- Li, H.-T.; Duymich, C.E.; Weisenberger, D.J.; Liang, G. Genetic and Epigenetic Alterations in Bladder Cancer. Int. Neurourol. J. 2016, 20, S84–S94. [Google Scholar] [CrossRef] [PubMed]
- Patschan, O.; Sjödahl, G.; Chebil, G.; Lövgren, K.; Lauss, M.; Gudjonsson, S.; Kollberg, P.; Eriksson, P.; Aine, M.; Månsson, W.; et al. A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma. Eur. Urol. 2015, 68, 824–832; discussion 835–836. [Google Scholar] [CrossRef] [PubMed]
- Hedegaard, J.; Lamy, P.; Nordentoft, I.; Algaba, F.; Høyer, S.; Ulhøi, B.P.; Vang, S.; Reinert, T.; Hermann, G.G.; Mogensen, K.; et al. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell 2016, 30, 27–42. [Google Scholar] [CrossRef]
- Rachakonda, P.S.; Hosen, I.; de Verdier, P.J.; Fallah, M.; Heidenreich, B.; Ryk, C.; Wiklund, N.P.; Steineck, G.; Schadendorf, D.; Hemminki, K.; et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc. Natl. Acad. Sci. USA 2013, 110, 17426–17431. [Google Scholar] [CrossRef]
- Pang, K.H.; Esperto, F.; Noon, A.P. Opportunities of next-generation sequencing in non-muscle invasive bladder cancer outcome prediction. Transl. Androl. Urol. 2017, 6, 1043–1048. [Google Scholar] [CrossRef]
- Tian, W.; Shan, B.; Zhang, Y.; Ren, Y.; Liang, S.; Zhao, J.; Zhao, X.; Peng, D.; Cai, S.; Wang, H. Association of high tumor mutation (TMB) with DNA damage repair (DDR) alterations and better prognosis in ovarian cancer. J. Clin. Oncol. 2018, 36, 5512. [Google Scholar] [CrossRef]
- Zhang, N.; Jiang, G.; Liu, X.; Na, R.; Wang, X.; Xu, J. Prediction of Bacillus Calmette-Guerin Response in Patients with Bladder Cancer after Transurethral Resection of Bladder Tumor by Using Genetic Variation Based on Genomic Studies. Biomed Res. Int. 2016, 2016, 9859021. [Google Scholar] [CrossRef]
- Zhang, Y. Understanding the gender disparity in bladder cancer risk: The impact of sex hormones and liver on bladder susceptibility to carcinogens. J. Environ. Sci. Health C Environ. Carcinog. Ecotoxicol. Rev. 2013, 31, 287–304. [Google Scholar] [CrossRef]
- Singh, A.V.; Chandrasekar, V.; Paudel, N.; Laux, P.; Luch, A.; Gemmati, D.; Tisato, V.; Prabhu, K.S.; Uddin, S.; Dakua, S.P. Integrative toxicogenomics: Advancing precision medicine and toxicology through artificial intelligence and OMICs technology. Biomed. Pharmacother. 2023, 163, 114784. [Google Scholar] [CrossRef] [PubMed]
- Bhatt, A.P.; Redinbo, M.R.; Bultman, S.J. The role of the microbiome in cancer development and therapy. CA Cancer J. Clin. 2017, 67, 326–344. [Google Scholar] [CrossRef] [PubMed]
- Jain, T.; Sharma, P.; Are, A.C.; Vickers, S.M.; Dudeja, V. New Insights Into the Cancer-Microbiome-Immune Axis: Decrypting a Decade of Discoveries. Front. Immunol. 2021, 12, 622064. [Google Scholar] [CrossRef] [PubMed]
- Hourigan, S.K.; Zhu, W.; Wong, W.S.W.; Clemency, N.C.; Provenzano, M.; Vilboux, T.; Niederhuber, J.E.; Deeken, J.; Chung, S.; McDaniel-Wiley, K.; et al. Studying the urine microbiome in superficial bladder cancer: Samples obtained by midstream voiding versus cystoscopy. BMC Urol. 2020, 20, 5. [Google Scholar] [CrossRef] [PubMed]
- Liu, F.; Liu, A.; Lu, X.; Zhang, Z.; Xue, Y.; Xu, J.; Zeng, S.; Xiong, Q.; Tan, H.; He, X.; et al. Dysbiosis signatures of the microbial profile in tissue from bladder cancer. Cancer Med. 2019, 8, 6904–6914. [Google Scholar] [CrossRef] [PubMed]
- Parra-Grande, M.; Oré-Arce, M.; Sánchez-Hellín, V. A differential bladder microbiota composition is associated with tumour grade in bladder cancer. Ann. Oncol. 2019, 30, v379. [Google Scholar] [CrossRef]
- Pederzoli, F.; Ferrarese, R.; Amato, V.; Locatelli, I.; Alchera, E.; Lucianò, R.; Nebuloni, M.; Briganti, A.; Gallina, A.; Colombo, R.; et al. Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients. Eur. Urol. Oncol. 2020, 3, 784–788. [Google Scholar] [CrossRef] [PubMed]
- Bi, H.; Tian, Y.; Song, C.; Li, J.; Liu, T.; Chen, Z.; Chen, C.; Huang, Y.; Zhang, Y. Urinary microbiota–A potential biomarker and therapeutic target for bladder cancer. J. Med. Microbiol. 2019, 68, 1471–1478. [Google Scholar] [CrossRef]
- Azevedo, M.M.; Pina-Vaz, C.; Baltazar, F. Microbes and Cancer: Friends or Faux? Int. J. Mol. Sci. 2020, 21, 3115. [Google Scholar] [CrossRef]
- Zeber-Lubecka, N.; Kulecka, M.; Załęska-Oracka, K.; Dąbrowska, M.; Bałabas, A.; Hennig, E.E.; Szymanek-Szwed, M.; Mikula, M.; Jurkiewicz, B.; Ostrowski, J. Gene Expression-Based Functional Differences between the Bladder Body and Trigonal Urothelium in Adolescent Female Patients with Micturition Dysfunction. Biomedicines 2022, 10, 1435. [Google Scholar] [CrossRef]
- Zeber-Lubecka, N.; Kulecka, M.; Lindner, B.; Krynicki, R.; Paziewska, A.; Nowakowski, A.; Bidzinski, M.; Ostrowski, J. Increased diversity of a cervical microbiome associates with cervical cancer. Front. Oncol. 2022, 12, 1005537. [Google Scholar] [CrossRef] [PubMed]
- Zeber-Lubecka, N.; Kulecka, M.; Ambrozkiewicz, F.; Paziewska, A.; Goryca, K.; Karczmarski, J.; Rubel, T.; Wojtowicz, W.; Mlynarz, P.; Marczak, L.; et al. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome. Gut Microbes 2016, 7, 397–413. [Google Scholar] [CrossRef] [PubMed]
- Bilski, K.; Dobruch, J.; Kozikowski, M.; Skrzypczyk, M.A.; Oszczudłowski, M.; Ostrowski, J. Urobiome in Gender-Related Diversities of Bladder Cancer. Int. J. Mol. Sci. 2020, 21, 4488. [Google Scholar] [CrossRef] [PubMed]
- Schloss, P.D.; Westcott, S.L.; Ryabin, T.; Hall, J.R.; Hartmann, M.; Hollister, E.B.; Lesniewski, R.A.; Oakley, B.B.; Parks, D.H.; Robinson, C.J.; et al. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 2009, 75, 7537–7541. [Google Scholar] [CrossRef] [PubMed]
- Edgar, R.C.; Haas, B.J.; Clemente, J.C.; Quince, C.; Knight, R. UCHIME improves sensitivity and speed of chimera detection. Bioinformatics 2011, 27, 2194–2200. [Google Scholar] [CrossRef] [PubMed]
- Silva, C.J.; Caparica, A.A.; Plascak, J.A. Wang-Landau Monte Carlo simulation of the Blume-Capel model. Phys. Rev. E Stat. Nonlinear Soft Matter Phys. 2006, 73, 36702. [Google Scholar] [CrossRef] [PubMed]
- Benjamini, Y.; Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B 1995, 57, 289–300. [Google Scholar] [CrossRef]
- Belkaid, Y.; Hand, T.W. Role of the microbiota in immunity and inflammation. Cell 2014, 157, 121–141. [Google Scholar] [CrossRef]
- Rea, D.; Coppola, G.; Palma, G.; Barbieri, A.; Luciano, A.; Del Prete, P.; Rossetti, S.; Berretta, M.; Facchini, G.; Perdonà, S.; et al. Microbiota effects on cancer: From risks to therapies. Oncotarget 2018, 9, 17915–17927. [Google Scholar] [CrossRef]
- Sears, C.L.; Garrett, W.S. Microbes, microbiota, and colon cancer. Cell Host Microbe 2014, 15, 317–328. [Google Scholar] [CrossRef]
- Grasso, F.; Frisan, T. Bacterial Genotoxins: Merging the DNA Damage Response into Infection Biology. Biomolecules 2015, 5, 1762–1782. [Google Scholar] [CrossRef] [PubMed]
- Villaseñor, T.; Madrid-Paulino, E.; Maldonado-Bravo, R.; Urbán-Aragón, A.; Pérez-Martínez, L.; Pedraza-Alva, G. Activation of the Wnt Pathway by Mycobacterium tuberculosis: A Wnt-Wnt Situation. Front. Immunol. 2017, 8, 50. [Google Scholar] [CrossRef]
- Huycke, M.M.; Moore, D.R. In vivo production of hydroxyl radical by Enterococcus faecalis colonizing the intestinal tract using aromatic hydroxylation. Free Radic. Biol. Med. 2002, 33, 818–826. [Google Scholar] [CrossRef]
- Nougayrède, J.-P.; Homburg, S.; Taieb, F.; Boury, M.; Brzuszkiewicz, E.; Gottschalk, G.; Buchrieser, C.; Hacker, J.; Dobrindt, U.; Oswald, E. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 2006, 313, 848–851. [Google Scholar] [CrossRef] [PubMed]
- Goodwin, A.C.; Destefano Shields, C.E.; Wu, S.; Huso, D.L.; Wu, X.; Murray-Stewart, T.R.; Hacker-Prietz, A.; Rabizadeh, S.; Woster, P.M.; Sears, C.L.; et al. Polyamine catabolism contributes to enterotoxigenic Bacteroides fragilis-induced colon tumorigenesis. Proc. Natl. Acad. Sci. USA 2011, 108, 15354–15359. [Google Scholar] [CrossRef]
- Gao, W.; Du, X.; Lei, L.; Wang, H.; Zhang, M.; Wang, Z.; Li, X.; Liu, G.; Li, X. NEFA-induced ROS impaired insulin signalling through the JNK and p38MAPK pathways in non-alcoholic steatohepatitis. J. Cell. Mol. Med. 2018, 22, 3408–3422. [Google Scholar] [CrossRef] [PubMed]
- Alexander, J.L.; Scott, A.J.; Pouncey, A.L.; Marchesi, J.; Kinross, J.; Teare, J. Colorectal carcinogenesis: An archetype of gut microbiota-host interaction. Ecancermedicalscience 2018, 12, 865. [Google Scholar] [CrossRef]
- Tilg, H.; Adolph, T.E.; Gerner, R.R.; Moschen, A.R. The Intestinal Microbiota in Colorectal Cancer. Cancer Cell 2018, 33, 954–964. [Google Scholar] [CrossRef]
- Raskov, H.; Burcharth, J.; Pommergaard, H.-C. Linking Gut Microbiota to Colorectal Cancer. J. Cancer 2017, 8, 3378–3395. [Google Scholar] [CrossRef]
- He, S.; Li, H.; Yu, Z.; Zhang, F.; Liang, S.; Liu, H.; Chen, H.; Lü, M. The Gut Microbiome and Sex Hormone-Related Diseases. Front. Microbiol. 2021, 12, 711137. [Google Scholar] [CrossRef]
- Mohseni, A.H.; Taghinezhad-S, S.; Casolaro, V.; Lv, Z.; Li, D. Potential links between the microbiota and T cell immunity determine the tumor cell fate. Cell Death Dis. 2023, 14, 154. [Google Scholar] [CrossRef] [PubMed]
- Santos-Marcos, J.A.; Mora-Ortiz, M.; Tena-Sempere, M.; Lopez-Miranda, J.; Camargo, A. Interaction between gut microbiota and sex hormones and their relation to sexual dimorphism in metabolic diseases. Biol. Sex Differ. 2023, 14, 4. [Google Scholar] [CrossRef] [PubMed]
- Nickel, J.C.; Stephens, A.; Ackerman, A.L.; Anger, J.T.; Lai, H.H.; Ehrlich, G.D. The healthy urinary microbiome in asymptomatic participants in the MAPP Network Study: Relation to gender, age, and menopausal status. Can. Urol. Assoc. J. 2022, 16, E448–E454. [Google Scholar] [CrossRef] [PubMed]
- Kandalai, S.; Li, H.; Zhang, N.; Peng, H.; Zheng, Q. The human microbiome and cancer: A diagnostic and therapeutic perspective. Cancer Biol. Ther. 2023, 24, 2240084. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.; Zhao, J.; Cao, Y.; Zhang, G.; Chen, Y.; Zhong, J.; Huang, W.; Zeng, J.; Wu, P. Relationship between alterations of urinary microbiota and cultured negative lower urinary tract symptoms in female type 2 diabetes patients. BMC Urol. 2019, 19, 78. [Google Scholar] [CrossRef] [PubMed]
- He, T.; Cheng, X.; Xing, C. The gut microbial diversity of colon cancer patients and the clinical significance. Bioengineered 2021, 12, 7046–7060. [Google Scholar] [CrossRef] [PubMed]
- Mekadim, C.; Skalnikova, H.K.; Cizkova, J.; Cizkova, V.; Palanova, A.; Horak, V.; Mrazek, J. Dysbiosis of skin microbiome and gut microbiome in melanoma progression. BMC Microbiol. 2022, 22, 63. [Google Scholar] [CrossRef] [PubMed]
- Pizzo, F.; Maroccia, Z.; Hammarberg Ferri, I.; Fiorentini, C. Role of the Microbiota in Lung Cancer: Insights on Prevention and Treatment. Int. J. Mol. Sci. 2022, 23, 6138. [Google Scholar] [CrossRef] [PubMed]
- Sims, T.T.; El Alam, M.B.; Karpinets, T.V.; Dorta-Estremera, S.; Hegde, V.L.; Nookala, S.; Yoshida-Court, K.; Wu, X.; Biegert, G.W.G.; Delgado Medrano, A.Y.; et al. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun. Biol. 2021, 4, 237. [Google Scholar] [CrossRef]
- Woo, Y.R.; Cho, S.H.; Lee, J.D.; Kim, H.S. The Human Microbiota and Skin Cancer. Int. J. Mol. Sci. 2022, 23, 1813. [Google Scholar] [CrossRef]
- Hrbáček, J.; Tláskal, V.; Čermák, P.; Hanáček, V.; Zachoval, R. Bladder cancer is associated with decreased urinary microbiota diversity and alterations in microbial community composition. Urol. Oncol. 2023, 41, 107.e15–107.e22. [Google Scholar] [CrossRef] [PubMed]
- Sánchez-Alcoholado, L.; Ramos-Molina, B.; Otero, A.; Laborda-Illanes, A.; Ordóñez, R.; Medina, J.A.; Gómez-Millán, J.; Queipo-Ortuño, M.I. The Role of the Gut Microbiome in Colorectal Cancer Development and Therapy Response. Cancers 2020, 12, 1406. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Cao, H.; Fei, B.; Gao, Q.; Yi, W.; Han, W.; Bao, C.; Xu, J.; Zhao, W.; Zhang, F. Gut Microbiota Signatures in Tumor, Para-Cancerous, Normal Mucosa, and Feces in Colorectal Cancer Patients. Front. Cell Dev. Biol. 2022, 10, 916961. [Google Scholar] [CrossRef] [PubMed]
- Sims, T.T.; Colbert, L.E.; Zheng, J.; Delgado Medrano, A.Y.; Hoffman, K.L.; Ramondetta, L.; Jazaeri, A.; Jhingran, A.; Schmeler, K.M.; Daniel, C.R.; et al. Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls. Gynecol. Oncol. 2019, 155, 237–244. [Google Scholar] [CrossRef] [PubMed]
- Zha, L.; Garrett, S.; Sun, J. Salmonella Infection in Chronic Inflammation and Gastrointestinal Cancer. Diseases 2019, 7, 28. [Google Scholar] [CrossRef] [PubMed]
- Mansour, B.; Monyók, Á.; Makra, N.; Gajdács, M.; Vadnay, I.; Ligeti, B.; Juhász, J.; Szabó, D.; Ostorházi, E. Bladder cancer-related microbiota: Examining differences in urine and tissue samples. Sci. Rep. 2020, 10, 11042. [Google Scholar] [CrossRef]
- Bučević Popović, V.; Šitum, M.; Chow, C.-E.T.; Chan, L.S.; Roje, B.; Terzić, J. The urinary microbiome associated with bladder cancer. Sci. Rep. 2018, 8, 12157. [Google Scholar] [CrossRef]
- Lawani-Luwaji, E.U.; Alade, T. Sphingomonadaceae: Protective against breast cancer? Bull. Natl. Res. Cent. 2020, 44, 191. [Google Scholar] [CrossRef]
- Wang, N.; Sun, T.; Xu, J. Tumor-related Microbiome in the Breast Microenvironment and Breast Cancer. J. Cancer 2021, 12, 4841–4848. [Google Scholar] [CrossRef]
- Xu, W.; Yang, L.; Lee, P.; Huang, W.C.; Nossa, C.; Ma, Y.; Deng, F.-M.; Zhou, M.; Melamed, J.; Pei, Z. Mini-review: Perspective of the microbiome in the pathogenesis of urothelial carcinoma. Am. J. Clin. Exp. Urol. 2014, 2, 57–61. [Google Scholar]
- Wu, P.; Zhang, G.; Zhao, J.; Chen, J.; Chen, Y.; Huang, W.; Zhong, J.; Zeng, J. Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China. Front. Cell. Infect. Microbiol. 2018, 8, 167. [Google Scholar] [CrossRef]
- Flemer, B.; Lynch, D.B.; Brown, J.M.R.; Jeffery, I.B.; Ryan, F.J.; Claesson, M.J.; O’Riordain, M.; Shanahan, F.; O’Toole, P.W. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut 2017, 66, 633–643. [Google Scholar] [CrossRef] [PubMed]
- Conlon, M.A.; Bird, A.R. The impact of diet and lifestyle on gut microbiota and human health. Nutrients 2014, 7, 17–44. [Google Scholar] [CrossRef] [PubMed]
- Rezasoltani, S.; Dabiri, H.; Asadzadeh-Aghdaei, H.; Sepahi, A.A.; Modarressi, M.H.; Nazemalhosseini-Mojarad, E. The gut microflora assay in patients with colorectal cancer: In feces or tissue samples? Iran. J. Microbiol. 2019, 11, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Verma, S.; Shankar, E.; Lin, S.; Singh, V.; Chan, E.R.; Cao, S.; Fu, P.; MacLennan, G.T.; Ponsky, L.E.; Gupta, S. Identification of Key Genes Associated with Progression and Prognosis of Bladder Cancer through Integrated Bioinformatics Analysis. Cancers 2021, 13, 5931. [Google Scholar] [CrossRef] [PubMed]
- Zeng, J.; Zhang, G.; Chen, C.; Li, K.; Wen, Y.; Zhao, J.; Wu, P. Alterations in Urobiome in Patients With Bladder Cancer and Implications for Clinical Outcome: A Single-Institution Study. Front. Cell. Infect. Microbiol. 2020, 10, 555508. [Google Scholar] [CrossRef] [PubMed]
- Seow, S.W.; Rahmat, J.N.B.; Mohamed, A.A.K.; Mahendran, R.; Lee, Y.K.; Bay, B.H. Lactobacillus species is more cytotoxic to human bladder cancer cells than Mycobacterium Bovis (bacillus Calmette-Guerin). J. Urol. 2002, 168, 2236–2239. [Google Scholar] [CrossRef]
- Naito, S.; Koga, H.; Yamaguchi, A.; Fujimoto, N.; Hasui, Y.; Kuramoto, H.; Iguchi, A.; Kinukawa, N. Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer. J. Urol. 2008, 179, 485–490. [Google Scholar] [CrossRef]
- Mone, N.S.; Syed, S.; Ravichandiran, P.; Kamble, E.E.; Pardesi, K.R.; Salunke-Gawali, S.; Rai, M.; Vikram Singh, A.; Prasad Dakua, S.; Park, B.-H.; et al. Synergistic and Additive Effects of Menadione in Combination with Antibiotics on Multidrug-Resistant Staphylococcus aureus: Insights from Structure-Function Analysis of Naphthoquinones. ChemMedChem 2023, 18, e202300328. [Google Scholar] [CrossRef]
Male | Female | |
---|---|---|
Number | 21 (51%) | 20 (49%) |
Mean age at TURBT | 82 | 79 |
Low-grade | 11 (52%) | 12 (60%) |
Non-invasive (Ta) | 7 (33%) | 8 (40%) |
Invasive (T1) | 4 (19%) | 4 (20%) |
High-grade | 10 (48%) | 8 (40%) |
Non-invasive (Ta) | 4 (19%) | 3 (15%) |
Invasive (T1) | 6 (29%) | 5 (25%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bilski, K.; Żeber-Lubecka, N.; Kulecka, M.; Dąbrowska, M.; Bałabas, A.; Ostrowski, J.; Dobruch, A.; Dobruch, J. Microbiome Sex-Related Diversity in Non-Muscle-Invasive Urothelial Bladder Cancer. Curr. Issues Mol. Biol. 2024, 46, 3595-3609. https://doi.org/10.3390/cimb46040225
Bilski K, Żeber-Lubecka N, Kulecka M, Dąbrowska M, Bałabas A, Ostrowski J, Dobruch A, Dobruch J. Microbiome Sex-Related Diversity in Non-Muscle-Invasive Urothelial Bladder Cancer. Current Issues in Molecular Biology. 2024; 46(4):3595-3609. https://doi.org/10.3390/cimb46040225
Chicago/Turabian StyleBilski, Konrad, Natalia Żeber-Lubecka, Maria Kulecka, Michalina Dąbrowska, Aneta Bałabas, Jerzy Ostrowski, Aleksandra Dobruch, and Jakub Dobruch. 2024. "Microbiome Sex-Related Diversity in Non-Muscle-Invasive Urothelial Bladder Cancer" Current Issues in Molecular Biology 46, no. 4: 3595-3609. https://doi.org/10.3390/cimb46040225